{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/113734","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT01102972","ctis_id":"","HasResults":"true","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"ASSURE","allocation":"Randomized","arm_groups":[{"arm_group_label":"ATV + ABC/3TC","arm_group_description":"Subjects will change to ATV 400mg administered as two 200mg capsules orally, once daily and to the fixed-dose combination tablet of ABC 600mg/3TC 300mg (EPZICOM) administered as one tablet orally, once daily for 48 weeks. The subject's pre-study RTV will be discontinued.","arm_type":"Experimental"},{"arm_group_label":"ATV + RTV + TDF/FTC","arm_group_description":"Subjects will continue their pre-study therapy, un-modified, of ATV 300mg administered as one capsule orally, once daily plus RTV 100mg administered orally, once daily plus fixed dose combination tablet tenofovir 300mg/emtricitabine 200mg administered as one tablet orally, once daily for 48 weeks.","arm_type":"Active Comparator"}],"assignment":"Parallel Assignment","brief_summary":"This study is designed to compare the efficacy and safety of simplifying therapy from a regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to a regimen of ATV + abacavir sulfate/lamivudine (ABC/3TC) without RTV in virologically suppressed, HIV-1 infected, HLA-B*5701 negative subjects for 48 weeks.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A Simplification Study of Unboosted Reyataz with Epzicom (ASSURE)","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:51:53","criteria":"Inclusion Criteria: - Subject is an adult (greater than or equal to 18 years) with documented HIV-1 infection - Subject is a male or female of non-childbearing potential (physiologically incapable of becoming pregnant, is pre-menarchal or post-menopausal) or child-bearing potential with a negative pregnancy test who agrees to avoid pregnancy by sexual abstinence or utilization of a highly effective method of birth control throughout the study period - Subject is receiving a once-daily regimen of ATV (300mg) + RTV (100mg) + TDF/FTC (300mg/200mg) for at least 6 months prior to or by the first day of screening. ATV + RTV + TDF/FTC must be the subejct's INITIAL regimen or FIRST or SECOND SWITCH regimen. If ATV + RTV + TDF/FTC is subject's first or second switch regimen, then subject may ONLY have received the following prior regimens: a) any currently licensed non-nucleoside reverse transcriptase inhibitor (NNRTI) + TDF/FTC or ZDV/3TC; b) RTV-boosted PI with TDF/FTC or ZDV/3TC; or c) an alternative regimen not listed above after approval by Sponsor. - Subject is virologically suppressed on ATV + RTV + TDF/FTC defined as HIV-1 RNA </=75 copies/mL at 2 consecutive timepoints, one of which is at Screening and the other at least 28 days prior to Screening Exclusion Criteria: - Subject has evidence of virologic failure - Subject has any known HIV genotyping results indicating HIV virus contains any of the following resistance mutations in reverse transcriptase including K65R, K70E, L74V, M184I/V or Y115F, a combination of two or more thymidine analog mutations including M41L, D67N, K70R, K219Q or E that include changes at either L210 or T215), or 3 or more of the following HIV-1 protease mutations associated with atazanavir resistance: D30, V32, M36, M46, I47, G48, I50, I54, A71, G73, V77, V82, I84, N88, and L90 - Subject is HLA-B*5701 positive - Subject has hypersensitivity to any component of the study drugs - SUbject is pregnant or breastfeeding - Subject is enrolled in one or more investigational drug protocols within 30 days of screening - Subject has an active Center for Disease Control and Prevention (CDC) Category C disease, except cutaneous Kaposi’s sarcoma not requiring systemic therapy during the trial - Subject has ongoing clinically relevant hepatitis at screening and/or positive for Hepatitis B (+ HbsAg) - Subject has a creatinine clearance <50 mL/min via the Cockcroft-Gault method - Subject has a verified Grade 4 laboratory abnormality at screening unless the Investigator can provide a compelling explanation (e.g. elevated CPK due to exercise) for the laboratory result(s) and has the assent of the Sponsor - Subject has any other laboratory abnormality or medical condition at screening, which, in the opinion of the investigator, would preclude the subject’s participation in the study - Subject has had an immunization within 30 days prior to first dose of investigational product - Subject has had any exposure to treatment with immunomodulating agents (such as systemic corticosteroids, interleukins, or interferons) or receipt of an HIV-1 immunotherapeutic vaccine within 90 days prior to screening. Subjects using inhaled corticosteroids or short-course systemic corticosteroids (less than or equal to 14 days) are eligible for enrollment. - Subject has had treatment with radiation therapy or cytotoxic chemotherapeutic agents within 90 days prior to screening, or has an anticipated need for these agents within the study period - Subject has had treatment within 30 days prior to first dose of investigational product for or an anticipated need during the study of any medications which can have interactions with the study medications, TDF, FTC, ABC, 3TC, ATV and/or RTV, as described in current product labelling - Subject has had treatment with any previous abacavir-containing regimen","detailed_description":"A prospective, randomized, multicenter, open-label study to compare the efficacy and safety of simplifying from a regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to ATV + abacavir sulfate/lamivudine (ABC/3TC) without RTV for 48 weeks in virologically suppressed, HIV-1 infected, HLA-B*5701 negative subjects. ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"297","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"345062f3-5f45-51a6-ad80-22d05e7e10e8","internal":{"content":null,"contentDigest":"07b0cc673d0a97276061852ce04b883d","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Subject is an adult (greater than or equal to 18 years) with documented HIV-1 infection - Subject is a male or female of non-childbearing potential (physiologically incapable of becoming pregnant, is pre-menarchal or post-menopausal) or child-bearing potential with a negative pregnancy test who agrees to avoid pregnancy by sexual abstinence or utilization of a highly effective method of birth control throughout the study period - Subject is receiving a once-daily regimen of ATV (300mg) + RTV (100mg) + TDF/FTC (300mg/200mg) for at least 6 months prior to or by the first day of screening. ATV + RTV + TDF/FTC must be the subejct's INITIAL regimen or FIRST or SECOND SWITCH regimen. If ATV + RTV + TDF/FTC is subject's first or second switch regimen, then subject may ONLY have received the following prior regimens: a) any currently licensed non-nucleoside reverse transcriptase inhibitor (NNRTI) + TDF/FTC or ZDV/3TC; b) RTV-boosted PI with TDF/FTC or ZDV/3TC; or c) an alternative regimen not listed above after approval by Sponsor. - Subject is virologically suppressed on ATV + RTV + TDF/FTC defined as HIV-1 RNA </=75 copies/mL at 2 consecutive timepoints, one of which is at Screening and the other at least 28 days prior to Screening Exclusion Criteria: - Subject has evidence of virologic failure - Subject has any known HIV genotyping results indicating HIV virus contains any of the following resistance mutations in reverse transcriptase including K65R, K70E, L74V, M184I/V or Y115F, a combination of two or more thymidine analog mutations including M41L, D67N, K70R, K219Q or E that include changes at either L210 or T215), or 3 or more of the following HIV-1 protease mutations associated with atazanavir resistance: D30, V32, M36, M46, I47, G48, I50, I54, A71, G73, V77, V82, I84, N88, and L90 - Subject is HLA-B*5701 positive - Subject has hypersensitivity to any component of the study drugs - SUbject is pregnant or breastfeeding - Subject is enrolled in one or more investigational drug protocols within 30 days of screening - Subject has an active Center for Disease Control and Prevention (CDC) Category C disease, except cutaneous Kaposi’s sarcoma not requiring systemic therapy during the trial - Subject has ongoing clinically relevant hepatitis at screening and/or positive for Hepatitis B (+ HbsAg) - Subject has a creatinine clearance <50 mL/min via the Cockcroft-Gault method - Subject has a verified Grade 4 laboratory abnormality at screening unless the Investigator can provide a compelling explanation (e.g. elevated CPK due to exercise) for the laboratory result(s) and has the assent of the Sponsor - Subject has any other laboratory abnormality or medical condition at screening, which, in the opinion of the investigator, would preclude the subject’s participation in the study - Subject has had an immunization within 30 days prior to first dose of investigational product - Subject has had any exposure to treatment with immunomodulating agents (such as systemic corticosteroids, interleukins, or interferons) or receipt of an HIV-1 immunotherapeutic vaccine within 90 days prior to screening. Subjects using inhaled corticosteroids or short-course systemic corticosteroids (less than or equal to 14 days) are eligible for enrollment. - Subject has had treatment with radiation therapy or cytotoxic chemotherapeutic agents within 90 days prior to screening, or has an anticipated need for these agents within the study period - Subject has had treatment within 30 days prior to first dose of investigational product for or an anticipated need during the study of any medications which can have interactions with the study medications, TDF, FTC, ABC, 3TC, ATV and/or RTV, as described in current product labelling - Subject has had treatment with any previous abacavir-containing regimen","interventions":[{"arm_group_label":"ATV + RTV + TDF/FTC","intervention_description":"atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg","intervention_name":"Reyataz + Norvir + Truvada","intervention_type":"Drug"},{"arm_group_label":"ATV + ABC/3TC","intervention_description":"atazanavir 400mg + abacavir 600mg/lamivudine 300mg","intervention_name":"Reyataz + Epzicom","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":["HIV-1","HIV"],"last_follow_up_date":"12/31/2012 00:00:00","links":[{"description":"ViiV Healthcare Website","url":"http://www.viivhealthcare.com"},{"description":"Click here for more information about Epzicom","url":"http://www.epzicom.com"},{"description":"Click here for more information about the ASSURE study","url":"http://www.theassurestudy.com"}],"locations":[{"City":"West Palm Beach","Latitude":"26.7153474","CountryDisplay":"United States","Longitude":"-80.0533253","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33401","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Minneapolis","Latitude":"44.9758391","CountryDisplay":"United States","Longitude":"-93.2571034","Name":"GSK Investigational Site","StateDisplay":"Minnesota","PostalCode":"55415","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Diego","Latitude":"32.749789","CountryDisplay":"United States","Longitude":"-117.1676501","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92103","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Chicago","Latitude":"41.9577761","CountryDisplay":"United States","Longitude":"-87.6556468","Name":"GSK Investigational Site","StateDisplay":"Illinois","PostalCode":"60613","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Newport Beach","Latitude":"33.615828","CountryDisplay":"United States","Longitude":"-117.9307584","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92663","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Bakersfield","Latitude":"35.3873576","CountryDisplay":"United States","Longitude":"-119.0168962","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"93301","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Memphis","Latitude":"35.1428747","CountryDisplay":"United States","Longitude":"-90.0523125","Name":"GSK Investigational Site","StateDisplay":"Tennessee","PostalCode":"38103","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Fort Pierce","Latitude":"27.3646705","CountryDisplay":"United States","Longitude":"-80.3101684","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"34982","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Newark","Latitude":"40.7350747","CountryDisplay":"United States","Longitude":"-74.1739057","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"07102","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Charlotte","Latitude":"35.1811188","CountryDisplay":"United States","Longitude":"-80.8488498","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"28209","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Beverly Hills","Latitude":"34.0661071","CountryDisplay":"United States","Longitude":"-118.3841777","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90211","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fountain Valley","Latitude":"33.7168761","CountryDisplay":"United States","Longitude":"-117.9600466","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92708","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lynchburg","Latitude":"37.4137536","CountryDisplay":"United States","Longitude":"-79.1422464","Name":"GSK Investigational Site","StateDisplay":"Virginia","PostalCode":"24501","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Washington","Latitude":"38.9042365","CountryDisplay":"United States","Longitude":"-77.0521289","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20037","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Wilton Manor","Latitude":"26.1603626","CountryDisplay":"United States","Longitude":"-80.138934","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33305","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"East Lansing","Latitude":"42.724305","CountryDisplay":"United States","Longitude":"-84.4796047","Name":"GSK Investigational Site","StateDisplay":"Michigan","PostalCode":"48824","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Washington","Latitude":"38.9191485","CountryDisplay":"United States","Longitude":"-77.0362967","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20009","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.0931603","CountryDisplay":"United States","Longitude":"-118.3783347","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90069","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Houston","Latitude":"29.7333171","CountryDisplay":"United States","Longitude":"-95.417519","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77098","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Phoenix","Latitude":"33.5079722","CountryDisplay":"United States","Longitude":"-112.1012912","Name":"GSK Investigational Site","StateDisplay":"Arizona","PostalCode":"85015","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Daytona Beach","Latitude":"29.240991","CountryDisplay":"United States","Longitude":"-81.0699462","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32117","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Chapel Hill","Latitude":"35.905249","CountryDisplay":"United States","Longitude":"-79.0581498","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"27599","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hillsborough","Latitude":"40.5106594","CountryDisplay":"United States","Longitude":"-74.6472522","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"08844","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Denver","Latitude":"39.7316982","CountryDisplay":"United States","Longitude":"-104.9213643","Name":"GSK Investigational Site","StateDisplay":"Colorado","PostalCode":"80220","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berkeley","Latitude":"42.5007019","CountryDisplay":"United States","Longitude":"-83.1916937","Name":"GSK Investigational Site","StateDisplay":"Michigan","PostalCode":"48072","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Orlando","Latitude":"28.5542151","CountryDisplay":"United States","Longitude":"-81.3454417","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32803","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Juan","Latitude":"18.4418194","CountryDisplay":"Puerto Rico","Longitude":"-66.0706255","Name":"GSK Investigational Site","StateDisplay":"Puerto Rico","PostalCode":"00909","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.8676889","CountryDisplay":"United States","Longitude":"-84.4645184","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30339","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Boise","Latitude":"43.6320897","CountryDisplay":"United States","Longitude":"-116.2863998","Name":"GSK Investigational Site","StateDisplay":"Idaho","PostalCode":"83704","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Spokane","Latitude":"47.6457534","CountryDisplay":"United States","Longitude":"-117.4253653","Name":"GSK Investigational Site","StateDisplay":"Washington","PostalCode":"99204","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7962048","CountryDisplay":"United States","Longitude":"-96.7694752","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75246","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Lauderdale","Latitude":"26.1897731","CountryDisplay":"United States","Longitude":"-80.1037721","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33308","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Valhalla","Latitude":"41.085128","CountryDisplay":"United States","Longitude":"-73.7772032","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10595","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Washington","Latitude":"38.9156487","CountryDisplay":"United States","Longitude":"-77.0737149","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20007","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Miami Beach","Latitude":"25.783312","CountryDisplay":"United States","Longitude":"-80.1484407","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33139","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Miami","Latitude":"25.7307897","CountryDisplay":"United States","Longitude":"-80.2377078","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33133","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Miami","Latitude":"25.8207159","CountryDisplay":"United States","Longitude":"-80.1819268","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33137","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.7971137","CountryDisplay":"United States","Longitude":"-84.3804888","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30309","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Francisco","Latitude":"37.7929789","CountryDisplay":"United States","Longitude":"-122.4212424","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94109","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ponce","Latitude":"18.0004826","CountryDisplay":"Puerto Rico","Longitude":"-66.6042494","Name":"GSK Investigational Site","StateDisplay":"Puerto Rico","PostalCode":"00717","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Kansas City","Latitude":"39.1040382","CountryDisplay":"United States","Longitude":"-94.5701803","Name":"GSK Investigational Site","StateDisplay":"Missouri","PostalCode":"64106","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hobson City","Latitude":"33.6214934","CountryDisplay":"United States","Longitude":"-85.8441318","Name":"GSK Investigational Site","StateDisplay":"Alabama","PostalCode":"36201","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Phoenix","Latitude":"33.5114334","CountryDisplay":"United States","Longitude":"-112.0685027","Name":"GSK Investigational Site","StateDisplay":"Arizona","PostalCode":"85012","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"SAVANNAH","Latitude":"32.081259","CountryDisplay":"United States","Longitude":"-81.0809848","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"31401","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Oakland","Latitude":"37.8015517","CountryDisplay":"United States","Longitude":"-122.2143323","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94602","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Long Beach","Latitude":"33.7844997","CountryDisplay":"United States","Longitude":"-118.1971031","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90813","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.7971137","CountryDisplay":"United States","Longitude":"-84.3804888","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30309","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Bakersfield","Latitude":"35.3873576","CountryDisplay":"United States","Longitude":"-119.0168962","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"93301","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Beverly Hills","Latitude":"34.0661071","CountryDisplay":"United States","Longitude":"-118.3841777","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90211","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Birmingham","Latitude":"33.5075555","CountryDisplay":"United States","Longitude":"-86.8093239","Name":"GSK Investigational Site","StateDisplay":"Alabama","PostalCode":"35294","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Boise","Latitude":"43.6320897","CountryDisplay":"United States","Longitude":"-116.2863998","Name":"GSK Investigational Site","StateDisplay":"Idaho","PostalCode":"83704","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Chapel Hill","Latitude":"35.905249","CountryDisplay":"United States","Longitude":"-79.0581498","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"27599","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Charlotte","Latitude":"35.1811188","CountryDisplay":"United States","Longitude":"-80.8488498","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"28209","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Chicago","Latitude":"41.8816606","CountryDisplay":"United States","Longitude":"-87.6926257","Name":"GSK Investigational Site","StateDisplay":"Illinois","PostalCode":"60612","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Chicago","Latitude":"41.9577761","CountryDisplay":"United States","Longitude":"-87.6556468","Name":"GSK Investigational Site","StateDisplay":"Illinois","PostalCode":"60613","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Dallas","Latitude":"32.7962048","CountryDisplay":"United States","Longitude":"-96.7694752","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75246","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Denver","Latitude":"39.7316982","CountryDisplay":"United States","Longitude":"-104.9213643","Name":"GSK Investigational Site","StateDisplay":"Colorado","PostalCode":"80220","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"East Lansing","Latitude":"42.724305","CountryDisplay":"United States","Longitude":"-84.4796047","Name":"GSK Investigational Site","StateDisplay":"Michigan","PostalCode":"48824","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Fort Lauderdale","Latitude":"26.1897731","CountryDisplay":"United States","Longitude":"-80.1037721","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33308","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Fort Pierce","Latitude":"27.3646705","CountryDisplay":"United States","Longitude":"-80.3101684","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"34982","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Fountain Valley","Latitude":"33.7168761","CountryDisplay":"United States","Longitude":"-117.9600466","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92708","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Hillsborough","Latitude":"40.5106594","CountryDisplay":"United States","Longitude":"-74.6472522","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"08844","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Houston","Latitude":"29.7050857","CountryDisplay":"United States","Longitude":"-95.4018087","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77030","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Houston","Latitude":"29.7333171","CountryDisplay":"United States","Longitude":"-95.417519","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77098","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Huntersville","Latitude":"35.410694","CountryDisplay":"United States","Longitude":"-80.8428504","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"28078","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Long Beach","Latitude":"33.7844997","CountryDisplay":"United States","Longitude":"-118.1971031","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90813","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Los Angeles","Latitude":"34.0931603","CountryDisplay":"United States","Longitude":"-118.3783347","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90069","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Memphis","Latitude":"35.1428747","CountryDisplay":"United States","Longitude":"-90.0523125","Name":"GSK Investigational Site","StateDisplay":"Tennessee","PostalCode":"38103","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Miami","Latitude":"25.9358702","CountryDisplay":"United States","Longitude":"-80.3268812","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33015","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Miami","Latitude":"25.7307897","CountryDisplay":"United States","Longitude":"-80.2377078","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33133","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Miami","Latitude":"25.7870967","CountryDisplay":"United States","Longitude":"-80.2042436","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33136","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Miami","Latitude":"25.8207159","CountryDisplay":"United States","Longitude":"-80.1819268","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33137","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Miami","Latitude":"25.7621935","CountryDisplay":"United States","Longitude":"-80.3129541","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33144","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Miami Beach","Latitude":"25.783312","CountryDisplay":"United States","Longitude":"-80.1484407","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33139","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Minneapolis","Latitude":"44.9758391","CountryDisplay":"United States","Longitude":"-93.2571034","Name":"GSK Investigational Site","StateDisplay":"Minnesota","PostalCode":"55415","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Newark","Latitude":"40.7350747","CountryDisplay":"United States","Longitude":"-74.1739057","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"07102","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Newport Beach","Latitude":"33.615828","CountryDisplay":"United States","Longitude":"-117.9307584","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92663","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Orlando","Latitude":"28.5542151","CountryDisplay":"United States","Longitude":"-81.3454417","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32803","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Palm Springs","Latitude":"33.8613433","CountryDisplay":"United States","Longitude":"-116.5727815","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92262","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Phoenix","Latitude":"33.5114334","CountryDisplay":"United States","Longitude":"-112.0685027","Name":"GSK Investigational Site","StateDisplay":"Arizona","PostalCode":"85012","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Sacramento","Latitude":"38.5500434","CountryDisplay":"United States","Longitude":"-121.4599012","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"95817","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Safety Harbor","Latitude":"28.0055309","CountryDisplay":"United States","Longitude":"-82.6861446","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"34695","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"San Antonio","Latitude":"29.5060908","CountryDisplay":"United States","Longitude":"-98.577596","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"78229","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"San Diego","Latitude":"32.749789","CountryDisplay":"United States","Longitude":"-117.1676501","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92103","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"San Francisco","Latitude":"37.7929789","CountryDisplay":"United States","Longitude":"-122.4212424","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94109","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"San Francisco","Latitude":"37.7813454","CountryDisplay":"United States","Longitude":"-122.497668","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94121","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Spokane","Latitude":"47.6457534","CountryDisplay":"United States","Longitude":"-117.4253653","Name":"GSK Investigational Site","StateDisplay":"Washington","PostalCode":"99204","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Tampa","Latitude":"27.9552692","CountryDisplay":"United States","Longitude":"-82.4563199","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33602","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Tampa","Latitude":"28.0133862","CountryDisplay":"United States","Longitude":"-82.5077593","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33614","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Toledo","Latitude":"41.5993157","CountryDisplay":"United States","Longitude":"-83.6295222","Name":"GSK Investigational Site","StateDisplay":"Ohio","PostalCode":"43614","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Washington","Latitude":"38.9191485","CountryDisplay":"United States","Longitude":"-77.0362967","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20009","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Washington","Latitude":"38.9080786","CountryDisplay":"United States","Longitude":"-77.0406147","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20036","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Washington","Latitude":"38.9042365","CountryDisplay":"United States","Longitude":"-77.0521289","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20037","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Wilton Manor","Latitude":"26.1603626","CountryDisplay":"United States","Longitude":"-80.138934","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33305","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"}],"masking":"Open Label","maximum_age_raw":"120 years","maximum_age":"120","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:26:21","number_of_arms":"2","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects","org_study_id":"113734","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 4","primary_compl_date":"06/25/2012 00:00:00","primary_outcomes":[],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"04/28/2010 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[{"citation":"D. Wohl, L. Bhatti, P. Maruff, K. Robertson, C. Small, H. Edelstein, H. Zhao, D. Margolis, L. Ross, M. Shaefer, on behalf of the ASSURE (EPZ113734) Study Team. Prevalence of HIV Associated Neurocognitive Disorders (HAND) in Virologically Suppressed HIV+ Individuals. 19th International AIDS Conference; July 22-27, 2012; Washington, DC. Poster WEPE092.","is_results_ref":"Yes","pubmed_id":""},{"citation":"Robertson K, Maruff P, Wohl D, et al. Similar cognition outcomes after 24 weeks for tenofovir/FTC + atazanavir/r (ATV/r)-experienced HIV+ subjects or subjects simplifying to abacavir/3TC+ATV. Published at: Conference on Retroviruses and Opportunistic Infections - 20th Annual; March 3-6, 2013; Atlanta, GA.","is_results_ref":"None","pubmed_id":""},{"citation":"C. B. Small, D. Wohl, D. A. Margolis, B. Wine, L. L. Ross, H. Zhao, and M. S. Shaefer. Prevalence of HLA-B*5701 Allele in HIV-infected Subjects in North America and Reductions in Risk for Development of Abacavir Associated Hypersensitivity Reaction (ABC HSR). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA. Poster H-895","is_results_ref":"Yes","pubmed_id":""},{"citation":"D. Wohl, L. Bhatti, C. B. Small, H. Edelstein, H. Zhao, D. A. Margolis, L. L. Ross, M.S. Shaefer. Simplification to Abacavir/Lamivudine (ABC/3TC) + Atazanavir (ATV) from Tenofovir/Emtricitabine (TDF/FTC) + ATV/Ritonavir (RTV, /r) Maintains Viral Suppression and Improves Bone Biomarkers. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA. Oral presentation H-556c.","is_results_ref":"Yes","pubmed_id":""}],"is_section_801":true}},"pageContext":{"studyId":"113734"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}